{"content":"<li class=\"n-box-item date-title\" data-end=\"1491364799\" data-start=\"1491278400\" data-txt=\"Monday, December 23, 2019\">Tuesday, April  4, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3255558\" data-ts=\"1491347107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INNL\" target=\"_blank\">INNL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255558-reuters-gurnet-point-capital-nears-deal-to-acquire-drugmaker-innocoll\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Gurnet Point Capital nears deal to acquire drugmaker Innocoll</a></h4><ul>     <li>Drugmaker Innocoll Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/INNL' title='Innocoll'>INNL</a>) <font color='green'>+57.7%</font>&nbsp;AH following a 42% surge in regular trade, as Reuters reports the company is <a href=\"http://uk.reuters.com/article/uk-innocoll-m-a-gurnetpointcapital-idUKKBN1762Z2\" target=\"_blank\">in M&amp;A talks</a> with P-E firm Gurnet Point Capital.</li>     <li>Gurnet's offer includes a cash component and a performance-based payment that could greatly enhance the value of the transaction if certain milestones are reached, according to the report, which also says a deal could be reached as soon as this week.</li>     <li>A deal would add INNL's suite of collagen-based medicines to Gurnet Point's portfolio of life science businesses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255558\" data-linked=\"Reuters: Gurnet Point Capital nears deal to acquire drugmaker Innocoll\" data-tweet=\"$INNL - Reuters: Gurnet Point Capital nears deal to acquire drugmaker Innocoll https://seekingalpha.com/news/3255558-reuters-gurnet-point-capital-nears-deal-to-acquire-drugmaker-innocoll?source=tweet\" data-url=\"https://seekingalpha.com/news/3255558-reuters-gurnet-point-capital-nears-deal-to-acquire-drugmaker-innocoll\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255556\" data-ts=\"1491346252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNIS\" target=\"_blank\">UNIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255556-unilifeminus-66-on-dire-financial-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unilife -66% on dire financial warning</a></h4><ul>     <li>Unilife (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIS' title='Unilife Corporation'>UNIS</a>) <font color='red'>-66.4%</font> AH, hitting new all-time lows, after <a href=\"https://seekingalpha.com/filing/3490856\" target=\"_blank\">warning</a> that it lacks the cash to fund operations past this week without falling below minimum cash and restricted cash balance requirements under its debt facilities.</li><li>UNIS says it received notice last week from a key customer for wearable  injectors that a program with the company would be placed on  hold; given the importance of the program, UNIS says a delay may hurt its ability to obtain financing.</li><li>UNIS says it is exploring bridge financing alternatives, but such financing likely would take the form of  debtor-in-possession financing in connection with Chapter 11 proceedings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255556\" data-linked=\"Unilife -66% on dire financial warning\" data-tweet=\"$UNIS - Unilife -66% on dire financial warning https://seekingalpha.com/news/3255556-unilifeminus-66-on-dire-financial-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3255556-unilifeminus-66-on-dire-financial-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255555\" data-ts=\"1491346030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255555-ncaa-basketball-pushes-cbs-to-another-ratings-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NCAA basketball pushes CBS to another ratings win</a></h4><ul>   <li>CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='green'>+0.5%</font>) ruled the ratings roost again last week, with a big <a href=\"http://www.startribune.com/stephen-colbert-reaches-another-late-night-milestone/418264813/\" target=\"_blank\">assist again from March Madness</a>.</li>    <li>The NCAA basketball tournament helped push the network to an average of 9.7M prime-time viewers, well ahead of second-place NBC (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+0.6%</font>) with 5.3M. Trailing those two were ABC (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-0.1%</font>), with 4.4M on average, Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-1.1%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-1.2%</font>) with 2.7M and Univision (<a href='https://seekingalpha.com/symbol/UVN' title='Univision'>UVN</a>) with 1.5M.</li>    <li>Basketball made up the top two individual programs (Oregon vs. North Carolina drew 18.83M viewers, while the network's studio show drew 16.03M), but other CBS hits made their mark: <i>NCIS</i> at No. 3 with 14.35M, <i>The Big Bang Theory</i> at No. 4 with 12.78M; <i>The ACM Awards</i> at No. 7 with 10.91M and <i>Bull</i> at No. 8 with 10.9M.</li>    <li>Cracking the top 10 from other networks: <i>The Walking Dead</i> (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color='green'>+1.8%</font>), No. 5 with 11.31M; <i>Dancing with the Stars</i> (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>), No. 6 with 11.12M; and a pair of showings of <i>The Voice</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) at 9 and 10 with 10.56M and 10.22M respectively.</li>    <li>Fox News ruled cable prime-time again, averaging 2.27M viewers, against MSNBC's 1.69M, ESPN's 1.61M, USA Network's 1.55M and HGTV's (<a href=\"http://seekingalpha.com/symbol/SNI\" target=\"_blank\">SNI</a> <font color='green'>+1%</font>) 1.48M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255555\" data-linked=\"NCAA basketball pushes CBS to another ratings win\" data-tweet=\"$FOX $FOX $FOXA - NCAA basketball pushes CBS to another ratings win https://seekingalpha.com/news/3255555-ncaa-basketball-pushes-cbs-to-another-ratings-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3255555-ncaa-basketball-pushes-cbs-to-another-ratings-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255550\" data-ts=\"1491342355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNRA\" target=\"_blank\">PNRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255550-panera-breadplus-13-bloomberg-reports-jab-holding-in-m-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Panera Bread +13% as Bloomberg reports JAB Holding in M&amp;A talks</a></h4><ul>     <li>Panera Bread (NASDAQ:<a href='https://seekingalpha.com/symbol/PNRA' title='Panera Bread Company'>PNRA</a>) <font color='green'>+13.1%</font>&nbsp;AH following a Bloomberg bulletin that privately held JAB Holding is <a href=\"https://www.bloomberg.com/news/articles/2017-04-04/jab-holding-in-advanced-talks-to-acquire-panera-bread\" target=\"_blank\">in advanced talks</a> to acquire the chain.</li>     <li>A Bloomberg report <a href=\"https://www.bloomberg.com/news/articles/2017-04-03/panera-is-exploring-possible-sale-after-receiving-interest\" target=\"_blank\">yesterday</a> suggested PNRA was exploring strategic options, including a potential sale, and listed JAB as a potential suitor along with the likes of Starbucks (NASDAQ:<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a>) and Domino's Pizza (NYSE:<a href='https://seekingalpha.com/symbol/DPZ' title='Domino&#39;s Pizza, Inc.'>DPZ</a>); speculation also includes McDonald's (NYSE:<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a>), Yum Brands (NYSE:<a href='https://seekingalpha.com/symbol/YUM' title='Yum! Brands, Inc.'>YUM</a>) and Restaurant Brands International (NYSE:<a href='https://seekingalpha.com/symbol/QSR' title='Restaurant Brands International Inc.'>QSR</a>).</li><li><strong>Update</strong>: Bloomberg reports that a deal could be announced as soon as this week, although no final agreement has been reached.</li>     <li>&ldquo;JAB&rsquo;s strategy of rolling up coffee and bakery chains [Keurig, Einstein Bakery, Caribou] - and its willingness to pay a premium to do so - would be consistent with a Panera acquisition,&rdquo; says Bernstein analyst Sara Senatore.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255550\" data-linked=\"Panera Bread +13% as Bloomberg reports JAB Holding in M&amp;A talks\" data-tweet=\"$PNRA $PNRA $SBUX - Panera Bread +13% as Bloomberg reports JAB Holding in M&amp;A talks https://seekingalpha.com/news/3255550-panera-breadplus-13-bloomberg-reports-jab-holding-in-m-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3255550-panera-breadplus-13-bloomberg-reports-jab-holding-in-m-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255549\" data-ts=\"1491341903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255549-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/LNDC' title='Landec Corporation'>LNDC</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/SHLM' title='A. Schulman, Inc.'>SHLM</a> <font color='green'>+6.5%</font>. <a href='https://seekingalpha.com/symbol/CHUBK' title='CommerceHub, Inc.'>CHUBK</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a> <font color='green'>+1.2%</font>. <a href='https://seekingalpha.com/symbol/WIX' title='Wix.com'>WIX</a> <font color='green'>+1.2%</font>. .</li><li><b>Top losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a> <font color='red'>-1.4%</font>. <a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Ltd. ADS'>SFUN</a> <font color='red'>-1.2%</font>. <a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='red'>-0.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255549\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$LNDC $SHLM $CHUBK - After Hours Gainers / Losers https://seekingalpha.com/news/3255549-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3255549-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255540\" data-ts=\"1491338330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255540-ftc-amazon-com-drop-appeals-over-in-app-purchase-refunds-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTC, Amazon.com drop appeals over in-app purchase refunds case</a></h4><ul>   <li>Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color='green'>+1.7%</font>) and the Federal Trade Commission have <a href=\"http://www.broadcastingcable.com/news/washington/ftc-amazon-agree-drop-app-decision-appeals/164640\" target=\"_blank\">agreed to drop appeals</a> in an case over refunds for children's in-app purchases.</li>    <li>That paves the way toward more than $70M in refunds, the FTC says. The case hinged on whether Amazon.com got parents' permission for charges made through software from Amazon's app store.</li>    <li>A mixed ruling led to both parties appealing the case, but now with a deal in place, refunds can begin.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255355-google-bull-heads-sidelines-amazon-worries\" target=\"_blank\">Google bull heads to sidelines on Amazon worries</a> (Apr. 04 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255540\" data-linked=\"FTC, Amazon.com drop appeals over in-app purchase refunds case\" data-tweet=\"$AMZN - FTC, Amazon.com drop appeals over in-app purchase refunds case https://seekingalpha.com/news/3255540-ftc-amazon-com-drop-appeals-over-in-app-purchase-refunds-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3255540-ftc-amazon-com-drop-appeals-over-in-app-purchase-refunds-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255528\" data-ts=\"1491337198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRVS\" target=\"_blank\">CRVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255528-early-stage-data-on-corvus-lead-product-candidate-spooks-investors-shares-plummet-50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early-stage data on Corvus&#39; lead product candidate spooks investors, shares plummet 50%</a></h4><ul><li>Thinly traded micro cap Corvus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CRVS' title='Corvus Pharmaceuticals'>CRVS</a> <font color='red'>-50.2%</font>) got roughed up today after it <a href=\"https://seekingalpha.com/pr/16790344-corvus-pharmaceuticals-announces-interim-results-ongoing-phase-1-1b-study-demonstrating\" target=\"_blank\">announced </a>interim data on lead product candidate CPI-444.</li><li>Preliminary results from a Phase 1/1b clinical trial assessing CPI-444 as monotherapy and in combination with atezolizumab (Roche's Tecentriq) in patients with a range of advanced solid tumors clearly fell short of investors' expectations. The data were presented today at the American Association for Cancer Research in Washington, DC.</li><li>Overall disease control rates &#40;DCR&#41;&nbsp;(complete responders, partial responders, those with stable disease) for CPI-444 alone and for the combination were 28% and 39%, respectively. DCRs for anti-PD-L1-naive patients and those resistant to anti-PD-L1 therapy in the two treatment cohorts were 45%, 28% and 30%, 46%, respectively.</li><li>On the safety front, no Grade 3 (serious) or Grade 4 (life-threatening) adverse events were observed with single agent CPI-444. The most common grade 1 or 2 adverse events were nausea (13%), pruritis (9%) and fatigue, fever, decreased appetite (each 7%). In the combination groups, three serious adverse events in two patients were reported: one with Grade 3 Coombs-positive autoimmune hemolytic anemia and one with Grade 4 aseptic autoimmune meningoencephalitis and thrombocytopenia. Both resolved when treatment was discontinued.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255528\" data-linked=\"Early-stage data on Corvus&#39; lead product candidate spooks investors, shares plummet 50%\" data-tweet=\"$CRVS - Early-stage data on Corvus&#39; lead product candidate spooks investors, shares plummet 50% https://seekingalpha.com/news/3255528-early-stage-data-on-corvus-lead-product-candidate-spooks-investors-shares-plummet-50?source=tweet\" data-url=\"https://seekingalpha.com/news/3255528-early-stage-data-on-corvus-lead-product-candidate-spooks-investors-shares-plummet-50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255522\" data-ts=\"1491334867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBRE\" target=\"_blank\">CBRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255522-kbw-trims-outlook-for-commercial-property-brokers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KBW trims outlook for commercial property brokers</a></h4><ul><li>U.S. commercial volumes in January and February were down 37% Y/Y, according to Real Capital Analytics. It's enough for KBW's Jade Rahmani to reduce his 2017-19 outlook for the commercial brokers by 2-4%.</li><li>Among those lower today: CBRE Group (CBG <font color='red'>-2.6%</font>), Jones Lang LaSalle (<a href='https://seekingalpha.com/symbol/JLL' title='Jones Lang Lasalle Inc.'>JLL</a> <font color='red'>-3.7%</font>), and HFF (<a href='https://seekingalpha.com/symbol/HF' title='HFF, Inc.'>HF</a> <font color='red'>-0.5%</font>).</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3255522\" data-linked=\"KBW trims outlook for commercial property brokers\" data-tweet=\"$CBRE $CBRE $JLL - KBW trims outlook for commercial property brokers https://seekingalpha.com/news/3255522-kbw-trims-outlook-for-commercial-property-brokers?source=tweet\" data-url=\"https://seekingalpha.com/news/3255522-kbw-trims-outlook-for-commercial-property-brokers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255518\" data-ts=\"1491333563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBA\" target=\"_blank\">PBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255518-pembina-pipelineplus-2-after-hiking-distribution-provides-updated-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pembina Pipeline +2% after hiking distribution, provides updated outlook</a></h4><ul>     <li>Pembina Pipeline (<a href='https://seekingalpha.com/symbol/PBA' title='Pembina Pipeline Corp.'>PBA</a> <font color='green'>+2%</font>) posts solid gains after late yesterday <a href=\"https://seekingalpha.com/news/3255285-pembina-pipeline-declares-cad-0_17-dividend\" target=\"_blank\">raising its monthly distribution</a> by 6.25% to C$0.17/share.</li>     <li>PBA also disclosed plans for a $75M expansion of its Fox Creek and Namao pump stations in Alberta as well as a new, 95-km pipeline connecting Lator to the Fox Creek station and costing ~$250M.</li>     <li>The upcoming projects are expected to expand capacity between Fox Creek and Namao by 180K bbl/day while the new pipeline will provide 260K bbl/day in capacity for the Montney and Deep Basin resource plays.</li>     <li>PBA expects 2018 adjusted EBITDA of C$1.8B-C$1.9B, consistent with its prior commitment of delivering  C$600M-C$950M of incremental fee-for-service EBITDA from Q2 capital projects which enter service in 2016-17.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255518\" data-linked=\"Pembina Pipeline +2% after hiking distribution, provides updated outlook\" data-tweet=\"$PBA - Pembina Pipeline +2% after hiking distribution, provides updated outlook https://seekingalpha.com/news/3255518-pembina-pipelineplus-2-after-hiking-distribution-provides-updated-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3255518-pembina-pipelineplus-2-after-hiking-distribution-provides-updated-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255515\" data-ts=\"1491332405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255515-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> GNCMA <font color='green'>+63%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TTMI' title='TTM Technologies, Inc.'>TTMI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255515\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$GLIBA $KONE $YGE - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3255515-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255515-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255514\" data-ts=\"1491332316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255514-petrobras-ceo-sees-debt-falling-below-target-year-end-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras CEO sees debt falling below target by year-end 2018</a></h4><ul>     <li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='green'>+1.8%</font>) could <a href=\"http://www.reuters.com/article/petrobras-ceo-debt-idUSL2N1HC0OZ\" target=\"_blank\">cut debt below a target of 2.5x EBITDA</a> by the end of next year if it maintains the current trend of debt reduction, CEO&nbsp;Pedro Parente says.</li>     <li>PBR's debt at the end of 2016 was 3.54x EBITDA, a sharp improvement over 2015 when the company finished the year at 5.11x EBITDA; its debt load of just under $100B ranks among the highest in the global oil industry.</li>     <li>Parente says the company's cash generation currently is at an \"extraordinary level\" and that the appreciation of the Brazilian real during the last four months has helped cut debt debt in dollar terms.</li>     <li>The CEO also says PBR's pre-salt fields have shown a productivity 30% above expectations, which has helped to reduce production costs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255514\" data-linked=\"Petrobras CEO sees debt falling below target by year-end 2018\" data-tweet=\"$PBR - Petrobras CEO sees debt falling below target by year-end 2018 https://seekingalpha.com/news/3255514-petrobras-ceo-sees-debt-falling-below-target-year-end-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3255514-petrobras-ceo-sees-debt-falling-below-target-year-end-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255508\" data-ts=\"1491329965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LBTYA\" target=\"_blank\">LBTYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255508-liberty-interactive-simplifies-structure-general-communication-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Liberty Interactive simplifies structure with General Communication deal</a></h4><ul>   <li>A Liberty Interactive (<a href=\"http://seekingalpha.com/symbol/QVCA\" target=\"_blank\">QVCA</a> <font color='green'>+2.4%</font>) deal to buy General Communication (<a href=\"http://seekingalpha.com/symbol/GNCMA\" target=\"_blank\">GNCMA</a> <font color='green'>+62%</font>) will mean benefits as Liberty Interactive loses its historical tracking stock discount, and narrow Liberty Ventures' (<a href=\"http://seekingalpha.com/symbol/LVNTA\" target=\"_blank\">LVNTA</a> <font color='green'>+10%</font>) NAV discount, analysts say.</li>    <li>Liberty will pay $32.50 in stock to General Communication shareholders, a 58% premium to yesterday's close. That's $27.50/share for shares of the combined GCI Liberty, and $5 in new Series A preferred shares (based on Liberty Ventures reference price of $43.65).</li>    <li>GCI Liberty should trade at a lower discount to NAV than current assets do, since it will run as an operating company with a more straightforward capital structure, says Evercore's James Ratcliffe. It also paves the way to consolidate Liberty's stake in Charter Communications (<a href=\"http://seekingalpha.com/symbol/CHTR\" target=\"_blank\">CHTR</a> <font color='green'>+1.3%</font>) by combining the new company with Charter.</li>    <li>Meanwhile, QVCA will be converted to a regular asset-backed stock, &ldquo;very helpful for broadening the base of investors who can look at it,\" says FBR's Barton Crockett, along with losing a tracking-stock discount.</li>    <li>Other possible beneficiaries from a simpler Liberty structure? Liberty Sirius (<a href=\"http://seekingalpha.com/symbol/LSXMA\" target=\"_blank\">LSXMA</a> <font color='green'>+1.4%</font>), Liberty Formula One (<a href=\"http://seekingalpha.com/symbol/FWONA\" target=\"_blank\">FWONA</a> <font color='green'>+0.7%</font>). <a href='https://seekingalpha.com/symbol/LBTYA' title='Liberty Global, Inc.'>LBTYA</a> <font color='green'>+0.6%</font>.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255508\" data-linked=\"Liberty Interactive simplifies structure with General Communication deal\" data-tweet=\"$LBTYA $LBTYA $QRTEA - Liberty Interactive simplifies structure with General Communication deal https://seekingalpha.com/news/3255508-liberty-interactive-simplifies-structure-general-communication-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3255508-liberty-interactive-simplifies-structure-general-communication-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255505\" data-ts=\"1491328811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255505-pareteum-names-new-worldwide-sales-chief-sets-investor-session\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum names new worldwide sales chief, sets investor session</a></h4><ul>   <li>Pareteum (<a href=\"http://seekingalpha.com/symbol/TEUM\" target=\"_blank\">TEUM</a> <font color='green'>+4.3%</font>) has named Robert Mumby to head its <a href=\"https://seekingalpha.com/pr/16789781-pareteum-strengthens-sales-organization-industry-veteran-lead-grow-worldwide-sales\" target=\"_blank\">worldwide sales efforts</a>.</li>    <li>Most recently, Mumby was director of Global Connectivity for Twilio, and prior to that servied in senior sales roles at Telus, Qwest and ITXC.</li>    <li>The company also said that Executive Chairman Hal Turner will host an <a href=\"http://public.viavid.com/index.php?id=123715\" target=\"_blank\">investor Q&amp;A session</a> tomorrow at 4:30 p.m. ET.</li>    <li>He'll respond to pre-submitted <a href=\"https://seekingalpha.com/pr/16789785-pareteum-executive-chairman-host-investor-q\" target=\"_blank\">investor questions</a> submitted by 3 p.m. ET today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255505\" data-linked=\"Pareteum names new worldwide sales chief, sets investor session\" data-tweet=\"$TEUM - Pareteum names new worldwide sales chief, sets investor session https://seekingalpha.com/news/3255505-pareteum-names-new-worldwide-sales-chief-sets-investor-session?source=tweet\" data-url=\"https://seekingalpha.com/news/3255505-pareteum-names-new-worldwide-sales-chief-sets-investor-session\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255501\" data-ts=\"1491328021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOGO\" target=\"_blank\">GOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255501-gogoplus-7_2-takes-lead-role-in-airbus-installation-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gogo +7.2% as it takes lead role in Airbus installation program</a></h4><ul>   <li>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a>) has <font color='green'>risen 7.2%</font> today after noting it's been <a href=\"https://seekingalpha.com/pr/16789444-gogo-named-supplier-airbus-high-bandwidth-connectivity-program\" target=\"_blank\">chosen by Airbus</a> as lead supplier for the airline's High Bandwidth Connectivity program.</li>    <li>That eases the way to factory line-fit installation of its 2Ku satellite solution on Airbus craft, to be arranged by airlines at the time they order the planes.</li>    <li>Gogo shares are <font color='green'>up 26.5%</font> YTD despite a one-month <font color='red'>drop of 3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255501\" data-linked=\"Gogo +7.2% as it takes lead role in Airbus installation program\" data-tweet=\"$GOGO - Gogo +7.2% as it takes lead role in Airbus installation program https://seekingalpha.com/news/3255501-gogoplus-7_2-takes-lead-role-in-airbus-installation-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3255501-gogoplus-7_2-takes-lead-role-in-airbus-installation-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255561\" data-ts=\"1491325855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPT\" target=\"_blank\">WPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255561-world-point-terminals-gets-takeout-proposal-16_80-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">World Point Terminals gets takeout proposal at $16.80/share</a></h4><ul><li>World Point Terminals (<a href='https://seekingalpha.com/symbol/WPT' title='World Point Terminals, LP'>WPT</a> <font color='green'>+4.5%</font>) discloses a <a href=\"https://www.sec.gov/Archives/edgar/data/1494927/000114420417018689/v463336_sc13da.htm\" target=\"_blank\">non-binding offer</a> from 66% shareholder World Point Terminals Inc. to take the company private for $16.80/share, a 2.7% premium to yesterday's closing price.</li><li>WPT owns and operates crude oil and refined product storage and terminals located across the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255561\" data-linked=\"World Point Terminals gets takeout proposal at $16.80/share\" data-tweet=\"$WPT - World Point Terminals gets takeout proposal at $16.80/share https://seekingalpha.com/news/3255561-world-point-terminals-gets-takeout-proposal-16_80-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3255561-world-point-terminals-gets-takeout-proposal-16_80-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255494\" data-ts=\"1491325413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255494-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/ICBK' title='County Bancorp'>ICBK</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/MBI' title='MBIA Inc.'>MBI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GLA' title='GlassBridge Enterprises, Inc.'>GLA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255494\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$AFSI $ICBK $CARV - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3255494-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255494-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255492\" data-ts=\"1491325193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255492-solar-stocks-rise-on-report-trump-considering-carbon-tax-to-raise-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solar stocks rise on report Trump considering carbon tax to raise revenue</a></h4><ul>     <li>First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='green'>+2.7%</font>) and other solar stocks pop higher following a <em>Washington Post</em> article saying the Trump administration is seriously <a href=\"https://www.washingtonpost.com/news/wonk/wp/2017/04/04/white-house-explores-two-new-tax-ideas-a-value-added-tax-and-carbon-tax-as-leading-proposal-to-raise-revenue-falters/?tid=sm_tw&amp;utm_term=.a3d6004f73d4\" target=\"_blank\">considering a carbon tax</a> among possible ways of increasing revenue as earlier talk of a border adjustment tax faces political challenges.</li>     <li>The White House also is looking at a value-added tax as part of a broader tax reform as the next major battleground for implementing its agenda.</li>     <li>A carbon tax and value-added tax long have been favored among  economists as revenue raising tools but have drawn skepticism from Republicans.</li>     <li>Other solar stocks are mostly higher: <a href='https://seekingalpha.com/symbol/SPWR' title='SunPower Corporation'>SPWR</a> <font color='green'>+4.3%</font>, <a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='green'>+2.3%</font>, <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+18%</font>, <a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='green'>+1.1%</font>, <a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd.'>SOL</a> <font color='green'>+7.5%</font>, <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+0.7%</font>, <a href='https://seekingalpha.com/symbol/JASO' title='JA Solar Holdings, Co., Ltd.'>JASO</a> <font color='green'>+0.6%</font>, <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/RUN' title='Sunrun'>RUN</a> <font color='red'>-0.5%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a>, <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/UTG' title='Reaves Utility Income Fund'>UTG</a>, <a href='https://seekingalpha.com/symbol/IDU' title='iShares U.S. Utilities ETF'>IDU</a>, <a href='https://seekingalpha.com/symbol/VPU' title='Vanguard Utilities ETF'>VPU</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/GUT' title='Gabelli Utility Trust'>GUT</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/BUI' title='BlackRock Utility&Infrastructure Trust'>BUI</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/FUTY' title='Fidelity MSCI Utilities Index ETF'>FUTY</a>, <a href='https://seekingalpha.com/symbol/RYU' title='Invesco S&P Equal Weight Utilities ETF'>RYU</a>, <a href='https://seekingalpha.com/symbol/UPW' title='ProShares Ultra Utilities ETF'>UPW</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/FXU' title='First Trust Utilities AlphaDEX ETF'>FXU</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3255492\" data-linked=\"Solar stocks rise on report Trump considering carbon tax to raise revenue\" data-tweet=\"$FSLR $FSLR $SPWR - Solar stocks rise on report Trump considering carbon tax to raise revenue https://seekingalpha.com/news/3255492-solar-stocks-rise-on-report-trump-considering-carbon-tax-to-raise-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3255492-solar-stocks-rise-on-report-trump-considering-carbon-tax-to-raise-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>140&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255482\" data-ts=\"1491324659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBLT\" target=\"_blank\">VBLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255482-vbl-advancing-new-oncology-therapeutic-target-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBL advancing new oncology therapeutic target; shares up 5%</a></h4><ul><li>Thinly traded micro cap VBL Therapeutics (<a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='green'>+5.3%</font>) perks up on modestly higher volume after the company <a href=\"https://seekingalpha.com/pr/16789505-vbl-therapeutics-presents-data-mospd2-novel-immuno-oncology-target\" target=\"_blank\">announced </a>new data on a novel potential cancer target called MOSPD2, a protein prevalent in breast cancer tissue correlated with more aggressive disease. The data are being presented today at the American Association for Cancer Research in Washington, DC.</li><li>In a mouse model, the use of gene editing technology CRISPR/Cas9 knocked down MOSPD2 which led to a blockade of EGF signaling and a significant reduction of breast cancer cell migration and metastasis.</li><li>The company believes that targeting MOSPD2 may have several therapeutic applications, including inhibition of tumor cell metastases and targeting of MOSPD2-positive tumor cells, as well as inhibition of monocyte migration in chronic inflammatory conditions. &nbsp;VBL's \"VB-600 series\" of pipeline candidates is being developed towards these applications.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255482\" data-linked=\"VBL advancing new oncology therapeutic target; shares up 5%\" data-tweet=\"$VBLT - VBL advancing new oncology therapeutic target; shares up 5% https://seekingalpha.com/news/3255482-vbl-advancing-new-oncology-therapeutic-target-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3255482-vbl-advancing-new-oncology-therapeutic-target-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255481\" data-ts=\"1491324560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255481-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> GNCMA <font color='green'>+62%</font>. <a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a> <font color='green'>+60%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/CALI' title='China Auto Logistics Inc.'>OTC:CALI</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a>&nbsp;<font color='green'>+15%</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-56%</font>. <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-54%</font>. <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255481\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$GLIBA $BNTC $CYCC - Midday Gainers / Losers https://seekingalpha.com/news/3255481-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3255481-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255471\" data-ts=\"1491323888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLT\" target=\"_blank\">FLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255471-fleetcorminus-5-citron-research-comes-out-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FleetCor -5% as Citron Research comes out negative</a></h4><ul>     <li>FleetCor Technologies (<a href='https://seekingalpha.com/symbol/FLT' title='FleetCor Technologies, Inc.'>FLT</a> <font color='red'>-4.6%</font>) after Citron Research issues a <a href=\"http://www.citronresearch.com/fleetcor-feecor-fleececor/\" target=\"_blank\">bearish report</a> that says the company's stock price <a href=\"https://www.streetinsider.com/Short+Sales/Citron+Research+Negative+on+Fleetcor+Technologies+%28FLT%29%3B+Sets+%24100+Short+Term+Price+Target/12741833.html\" target=\"_blank\">should sink to $100</a> \"as the truth... becomes more apparent to regulators and its customers.\"</li>     <li>FLT is \"a predatory company by design, whose core strategy is to methodically rip off its customers, using business practices and fees that are designed to deceive,\" according to the report.</li>     <li>Citron says competitor WEX&nbsp;(<a href='https://seekingalpha.com/symbol/WEX' title='WEX Inc.'>WEX</a> <font color='red'>-1.2%</font>), which has a broader distribution gas station network, has customer fees that are only 12% of revenue, compared to FLT's fees which are a \"staggering\" 56% of revenue.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255471\" data-linked=\"FleetCor -5% as Citron Research comes out negative\" data-tweet=\"$FLT $FLT $WEX - FleetCor -5% as Citron Research comes out negative https://seekingalpha.com/news/3255471-fleetcorminus-5-citron-research-comes-out-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3255471-fleetcorminus-5-citron-research-comes-out-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255470\" data-ts=\"1491323491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255470-diffusion-nabs-new-patent-covering-lead-product-candidate-shares-ahead-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion nabs new patent covering lead product candidate; shares ahead 18%</a></h4><ul><li>The USPTO issues U.S. Patent No. 9,604,899 to Diffusion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+17.6%</font>) protecting lead product candidate trans sodium crocetinate &#40;TSC&#41;. The patent expands the range of therapeutic uses of TSC and related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease and respiratory distress syndrome.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255470\" data-linked=\"Diffusion nabs new patent covering lead product candidate; shares ahead 18%\" data-tweet=\"$DFFN - Diffusion nabs new patent covering lead product candidate; shares ahead 18% https://seekingalpha.com/news/3255470-diffusion-nabs-new-patent-covering-lead-product-candidate-shares-ahead-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3255470-diffusion-nabs-new-patent-covering-lead-product-candidate-shares-ahead-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255469\" data-ts=\"1491323213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NJR\" target=\"_blank\">NJR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255469-wsj-new-jersey-resources-south-jersey-industries-holding-merger-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: New Jersey Resources, South Jersey Industries holding merger talks</a></h4><ul>     <li>New Jersey Resources (<a href='https://seekingalpha.com/symbol/NJR' title='New Jersey Resources Corporation'>NJR</a> <font color='green'>+2%</font>) and South Jersey Industries (<a href='https://seekingalpha.com/symbol/SJI' title='South Jersey Industries Inc.'>SJI</a> <font color='green'>+3%</font>) are <a href=\"https://www.wsj.com/articles/utilities-new-jersey-resources-south-jersey-industries-hold-merger-talks-1491322741\" target=\"_blank\">holding merger talks</a> that would bring together two natural gas utilities in the state, <em>WSJ</em> reports.</li><li>No further details are known, according to the report.</li>     <li>Rising revenue has fueled takeover interest in&nbsp;natural gas producers, and there has been a flurry of deal making over the past year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255469\" data-linked=\"WSJ: New Jersey Resources, South Jersey Industries holding merger talks\" data-tweet=\"$NJR $NJR $SJI - WSJ: New Jersey Resources, South Jersey Industries holding merger talks https://seekingalpha.com/news/3255469-wsj-new-jersey-resources-south-jersey-industries-holding-merger-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3255469-wsj-new-jersey-resources-south-jersey-industries-holding-merger-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255462\" data-ts=\"1491321636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255462-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FENX' title='Fenix Parts'>OTC:FENX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255462\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KATE $CYRX $FENX - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3255462-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255462-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255457\" data-ts=\"1491321052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNTC\" target=\"_blank\">BNTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255457-encouraging-preclinical-data-support-rationale-of-benitecs-bbminus-301-shares-ahead-55\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Encouraging preclinical data support rationale of Benitec&#39;s BB-301; shares ahead 55%</a></h4><ul><li>Nano cap Benitec Biopharma (<a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a> <font color='green'>+54.7%</font>) spikes on a healthy 28x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/16789619-key-pre-clinical-data-oculopharyngeal-muscular-dystrophy-opmd-published-nature-communications\" target=\"_blank\">announcement </a>of preclinical data published in <em>Nature Communications</em> that show the potential of a DNA-directed RNA interference (ddRNAi) approach to treating oculopharyngeal muscular dystrophy &#40;OPMD&#41;, a rare progressive muscle-wasting disorder caused by mutations in a gene called poly&#40;A&#41;-binding protein nuclear 1 (PABPN1).</li><li>Data from a mouse model showed that employing ddRNAi to \"silence and replace\" the mutant PABPN1 protein corrected the muscular dystrophy and the clinical features of progressive atrophy and muscle weakness.</li><li>The company and its collaborators have been working on BB-301, Benitec's next-generation ddRNAi therapeutic for the potential treatment of OPMD that combines the \"silence and replace\" strategy of mutant PABPN1 into a single vector. A Phase 1/2 study in OPMD&nbsp;is on tap for next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255457\" data-linked=\"Encouraging preclinical data support rationale of Benitec&#39;s BB-301; shares ahead 55%\" data-tweet=\"$BNTC - Encouraging preclinical data support rationale of Benitec&#39;s BB-301; shares ahead 55% https://seekingalpha.com/news/3255457-encouraging-preclinical-data-support-rationale-of-benitecs-bbminus-301-shares-ahead-55?source=tweet\" data-url=\"https://seekingalpha.com/news/3255457-encouraging-preclinical-data-support-rationale-of-benitecs-bbminus-301-shares-ahead-55\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255456\" data-ts=\"1491320986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255456-nvidiaminus-6-pacific-crest-drops-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia -6% as Pacific Crest drops to Underweight</a></h4><ul>   <li>Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) is <font color='red'>off 6%</font> to a three-week low after a Pacific Crest downgrade to Underweight, from Sector Weight.</li>    <li>The firm cut its EPS estimates for fiscal 2018 to $2.50 from $2.60 (GAAP consensus is $2.82 and non-GAAP consensus is $3.33), and for fiscal 2019 to $3.00 from $3.30 (GAAP consensus is $3.30 and non-GAAP $3.82).</li>    <li>Analyst Mike McConnell sees <a href=\"https://www.streetinsider.com/Analyst+Comments/Pacific+Crest+Downgrades+NVIDIA+%28NVDA%29+to+Underweight%2C+Sees+Downside+To+%2490/12739724.html\" target=\"_blank\">desktop PCs becoming saturated</a> and a possible pause in Datacenter business, all against an environment of no growth for desktop graphics card makers. He also sees a $0.10 impact to EPS based on low-margin Nintendo Switch revenue.</li>    <li>He has a price target of $105.15, implying just 3% upside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255456\" data-linked=\"Nvidia -6% as Pacific Crest drops to Underweight\" data-tweet=\"$NVDA - Nvidia -6% as Pacific Crest drops to Underweight https://seekingalpha.com/news/3255456-nvidiaminus-6-pacific-crest-drops-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3255456-nvidiaminus-6-pacific-crest-drops-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>90&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255450\" data-ts=\"1491319317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTG\" target=\"_blank\">PSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255450-pure-storageplus-4_3-susquehanna-boosts-to-positive\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pure Storage +4.3% as Susquehanna boosts to positive</a></h4><ul>    <li>Pure Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a>) is <font color='green'>up 4.3%</font> after a boost to positive at Susquehanna, which likes what it sees in future revenue growth and says the Street may not be appreciating operating leverage.</li>    <li>The company can grow revenues at 28% (compounded) annually from 2016-2019 just from FlashArray, and then new product revenue from FlashBlade amounts to \"pure upside.\"</li>    <li>Analyst Mehdi Hosseini boosted the firm's price target on <a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a> to $15 from $12, implying 41% upside from here.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255450\" data-linked=\"Pure Storage +4.3% as Susquehanna boosts to positive\" data-tweet=\"$PSTG - Pure Storage +4.3% as Susquehanna boosts to positive https://seekingalpha.com/news/3255450-pure-storageplus-4_3-susquehanna-boosts-to-positive?source=tweet\" data-url=\"https://seekingalpha.com/news/3255450-pure-storageplus-4_3-susquehanna-boosts-to-positive\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255444\" data-ts=\"1491318483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255444-analysts-defend-newlinks-indoximod-data-shares-slump-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts defend NewLink&#39;s indoximod data as shares slump 19%</a></h4><ul><li>Bullish analysts rush in to defend their Buy ratings on NewLink Genetics (<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-19.2%</font>) in the midst of a sell-off stoked by less-than-impressive data on IDO inhibitor indoximod.</li><li>SunTrust's Peter Lawson: Data in larger group of patients compared Incyte's data on IDO inhibitor epacadostat. NLNK's (combo)&nbsp;reported response rate \"looks more comparable\" to epacadostat when ocular melanoma excluded. Reiterated Buy rating with a $30 (59% upside) price target.</li><li>Cantor Fitzgerald's Mara Goldstein: Data \"looks competitive\" on responses as well as disease control rates. Profile of NLNK's Roche-partnered GDC-0919 may be raised on the basis of today's data. Rating: Buy.</li><li>Stifel Nicolaus' Stephen Willey: \"Incrementally positive\" after combo data. Recommends \"buy on weakness\" ahead of GDC-0919 data. Rating: Buy with $26 (40% upside) price target.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3255444\" data-linked=\"Analysts defend NewLink&#39;s indoximod data as shares slump 19%\" data-tweet=\"$NLNK - Analysts defend NewLink&#39;s indoximod data as shares slump 19% https://seekingalpha.com/news/3255444-analysts-defend-newlinks-indoximod-data-shares-slump-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3255444-analysts-defend-newlinks-indoximod-data-shares-slump-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255429\" data-ts=\"1491318061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255429-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+63%</font>. <a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a> <font color='green'>+54%</font>. <a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/GBSN-OLD' title='Great Basin Scientific, Inc.'>GBSN</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+21%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-44%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255429\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CYCC $BNTC $PRTK - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3255429-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3255429-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255445\" data-ts=\"1491317589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANF\" target=\"_blank\">ANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255445-mall-stocks-slide-after-weak-trend-pop-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mall stocks slide after more weak trend pop up</a></h4><ul> <li>The mall sector is seeing some selling pressure after Urban Outfitters updates on Q1 sales and Citi issues a harsh downgrade on L Brands.</li> <li>Also in the mix, the latest report from The Retail Economist/Goldman Sachs on weekly chain store sales showed a 1.7% decline (0.3% Y/Y).</li> <li>Decliners include Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch'>ANF</a> <font color='red'>-4.3%</font>), Ascena Retail Group (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-3.5%</font>), New York Company (NWY <font color='red'>-5.9%</font>), Boot Barn Holdings (<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='red'>-2.5%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='red'>-2.1%</font>), Christopher &amp; Banks (<a href='https://seekingalpha.com/symbol/CBK' title='Christopher & Banks Corporation'>CBK</a> <font color='red'>-3.5%</font>), Nordstrom (<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='red'>-2.6%</font>), DSW (<a href='https://seekingalpha.com/symbol/DSW' title='DSW Inc.'>DSW</a> <font color='red'>-2.3%</font>), American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color='red'>-2.7%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color='red'>-2.6%</font>), Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-3.9%</font>), Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-2.9%</font>) and Sears Holdings (SHLD <font color='red'>-1.5%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255427-multi-year-low-l-brands\" target=\"_blank\">Multi-year low for L Brands</a> (April 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255372-urban-outfitters-lower-sales-update\" target=\"_blank\">Urban Outfitters lower after sales update</a> (April 4)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3255445\" data-linked=\"Mall stocks slide after more weak trend pop up\" data-tweet=\"$ANF $ANF $ASNA - Mall stocks slide after more weak trend pop up https://seekingalpha.com/news/3255445-mall-stocks-slide-after-weak-trend-pop-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3255445-mall-stocks-slide-after-weak-trend-pop-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255443\" data-ts=\"1491317305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTU\" target=\"_blank\">BTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255443-peabody-energy-lower-in-nyse-return-lagging-coal-names\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peabody Energy lower in NYSE return, lagging other coal names</a></h4><ul>     <li>Peabody Energy's (<a href='https://seekingalpha.com/symbol/BTU' title='Peabody Energy Corp.'>BTU</a> <font color='red'>-3.3%</font>) NYSE debut after <a href=\"https://seekingalpha.com/news/3255284-peabody-energy-exits-chapter-11-will-list-nyse-tomorrow\" target=\"_blank\">exiting Chapter 11 bankruptcy</a> isn't going so well, with shares down more than 3%, but the bigger point is that the company is back after nearly a year in bankruptcy.</li>     <li>BTU, which produces more tons of coal than any other U.S. miner, returns with ~25% of its old debt levels and plans to focus on the thermal coal used by power plants which it can extract from mines in Wyoming and Australia that analysts rank <a href=\"https://www.bloomberg.com/news/articles/2017-04-03/america-s-biggest-coal-miner-is-joining-a-comeback-under-trump\" target=\"_blank\">among the world&rsquo;s lowest-cost operations</a>.</li>     <li>Other coal stocks are mostly higher today as <a href=\"https://www.bloomberg.com/news/articles/2017-04-04/coking-coal-surges-after-cyclone-debbie-cut-australian-supplies\" target=\"_blank\">coking coal prices shoot higher</a> after cyclone damage hits shipments from Australia: <a href='https://seekingalpha.com/symbol/ARCH' title='Arch Coal Inc'>ARCH</a> <font color='green'>+3.2%</font>, <a href='https://seekingalpha.com/symbol/CLD' title='Cloud Peak Energy, Inc.'>CLD</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='green'>+2.7%</font>, <a href='https://seekingalpha.com/symbol/ARLP' title='Alliance Resource Partners, L.P.'>ARLP</a> <font color='red'>-1.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255443\" data-linked=\"Peabody Energy lower in NYSE return, lagging other coal names\" data-tweet=\"$BTU $BTU $ARCH - Peabody Energy lower in NYSE return, lagging other coal names https://seekingalpha.com/news/3255443-peabody-energy-lower-in-nyse-return-lagging-coal-names?source=tweet\" data-url=\"https://seekingalpha.com/news/3255443-peabody-energy-lower-in-nyse-return-lagging-coal-names\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255439\" data-ts=\"1491316710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XTLB\" target=\"_blank\">XTLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255439-xtl-bio-finance-chief-bids-adieu-shares-ease-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XTL Bio finance chief bids adieu; shares ease 7%</a></h4><ul><li>Thinly traded nano cap XTL Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/XTLB' title='XTL Biopharmaceuticals Ltd.'>XTLB</a> <font color='red'>-6.9%</font>) slips on light volume in early trading. This morning, the company <a href=\"https://seekingalpha.com/filing/3488502\" target=\"_blank\">reported </a>that CFO David Kestenbaum informed the company that he will resign to pursue other opportunities. A search for a successor is underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255439\" data-linked=\"XTL Bio finance chief bids adieu; shares ease 7%\" data-tweet=\"$XTLB - XTL Bio finance chief bids adieu; shares ease 7% https://seekingalpha.com/news/3255439-xtl-bio-finance-chief-bids-adieu-shares-ease-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3255439-xtl-bio-finance-chief-bids-adieu-shares-ease-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255436\" data-ts=\"1491316157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONTX\" target=\"_blank\">ONTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255436-onconova-announces-encouraging-preclinical-data-on-two-aml-candidates-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Onconova announces encouraging preclinical data on two AML candidates; shares ahead 13%</a></h4><ul><li>Onconova Therapeutics (<a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+13.3%</font>) heads north on a healthy 39x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16789924-onconova-therapeutics-announces-positive-preclinical-data-third-generation-oral-cdk4-6-ark5\" target=\"_blank\">announcement </a>of positive preclinical data on two acute myeloid leukemia &#40;AML&#41; candidates, ON 123300 and ON 150030. The results were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.</li><li>In a xenograft (graft of tissue from one animal species to another) model ON 123300, a third-generation CDK4/6 inhibitor, demonstrated that it was as effective as Pfizer's Ibrance (palbociclib) with potentially less neutropenia (abnormally low levels of neutrophils in the blood). Both compounds reduced red blood cell and platelet counts, however.</li><li>Studies at the Icahn School of Mount Sinai showed that ON 150030, a type 1 inhibitor, specifically restricts the growth of a particular type of cells (MV4-11) that harbor a genetic mutation called FLT3-ITD. AML patients with this mutation have a poor prognosis.</li><li>The company says the two compounds represent a promising dual targeting strategy for treatment-resistant AML.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255436\" data-linked=\"Onconova announces encouraging preclinical data on two AML candidates; shares ahead 13%\" data-tweet=\"$ONTX - Onconova announces encouraging preclinical data on two AML candidates; shares ahead 13% https://seekingalpha.com/news/3255436-onconova-announces-encouraging-preclinical-data-on-two-aml-candidates-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3255436-onconova-announces-encouraging-preclinical-data-on-two-aml-candidates-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255433\" data-ts=\"1491315338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSGN\" target=\"_blank\">MSGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255433-msg-networksplus-7_4-on-report-looking-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MSG Networks +7.4% on report it&#39;s looking to sell</a></h4><ul>   <li>MSG Networks (NYSE:<a href='https://seekingalpha.com/symbol/MSGN' title='MSG Networks'>MSGN</a>) is <font color='green'>up 7.4%</font> after the <i>New York Post</i> reported that the company is <a href=\"http://nypost.com/2017/04/03/msg-networks-is-looking-to-sell/\" target=\"_blank\">listening to purchase offers</a>.</li>    <li>It's very early stages, the paper says, but \"(James) Dolan's gone to his friends\" -- including boardmember and Guggenheim Partners Executive Chairman Alan Schwartz -- to feel it out. The company's EV is about $3B, $1.7B in market cap.</li>    <li>The networks business spun out from the Madison Square Garden sports/entertainment business in late 2015. And &ldquo;I think the point of the spin-off was to sell the cable business a year or two later,&rdquo; one analyst says.</li>    <li>Who needs content? Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-0.4%</font>), for one. AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='red'>-0.3%</font>) is a possibility but already owns five regional sports nets and needs to focus on its Time Warner acquisition; Fox Sports (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-0.4%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-0.4%</font>) already covers New York with its YES Network. And Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+0.5%</font>), already there with a stake in SNY, may be looking for its own exit.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255433\" data-linked=\"MSG Networks +7.4% on report it&#39;s looking to sell\" data-tweet=\"$MSGN $MSGN $FOX - MSG Networks +7.4% on report it&#39;s looking to sell https://seekingalpha.com/news/3255433-msg-networksplus-7_4-on-report-looking-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3255433-msg-networksplus-7_4-on-report-looking-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255432\" data-ts=\"1491315332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255432-seadrillminus-40-after-shareholder-warning-of-substantial-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill -40% after shareholder warning of substantial losses</a></h4><ul>     <li>Seadrill (<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-39.2%</font>) plunges as much as 46% to record lows in early trading after warning investors to <a href=\"https://seekingalpha.com/news/3255310-warning-seadrill-shareholders\" target=\"_blank\">brace for \"substantial losses\"</a> in the face of potential bankruptcy proceedings.</li>     <li>SDRL says it won more breathing space to try to secure an agreement, including an extension of the deadline, to implement a restructuring plan from the end of this month to July 31.</li>     <li>While SDRL already had warned shareholders that they face dilution in a restructuring deal, the latest statement is &ldquo;an <a href=\"https://www.bloomberg.com/news/articles/2017-04-04/seadrill-reaches-extension-on-debt-talks-as-it-warns-on-losses\" target=\"_blank\">even clearer sign</a> from the company that the value for existing shareholders will be lower than what is priced in the equity market,&rdquo; says SpareBank 1 Markets analyst Vidar Lyngvaer.</li><li>Also: <a href='https://seekingalpha.com/symbol/SDLP' title='Seadrill Partners, LLC'>SDLP</a> <font color='red'>-7.2%</font>, <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-29.7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255432\" data-linked=\"Seadrill -40% after shareholder warning of substantial losses\" data-tweet=\"$SDRL $SDRL $SDLPF - Seadrill -40% after shareholder warning of substantial losses https://seekingalpha.com/news/3255432-seadrillminus-40-after-shareholder-warning-of-substantial-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3255432-seadrillminus-40-after-shareholder-warning-of-substantial-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255431\" data-ts=\"1491315307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLS\" target=\"_blank\">SPLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255431-staplesplus-14-pe-interest-in-mix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Staples +14% with PE interest in the mix</a></h4><ul>     <li>Staples (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLS' title='Staples, Inc.'>SPLS</a>)&nbsp;is talking to a \"small\" number of private equity firms about a <a href=\"https://www.wsj.com/articles/staples-explores-sale-1491313493\" target=\"_blank\">buyout</a>, according to The Wall Street Journal.</li>     <li>Shares are <font color='green'>up 13.63%</font> to $9.84 to give the company a market cap of around $6.34B. The WSJ sees a buyout going off at around a $7B valuation.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3255415-staples-spikes-buyout-report\" target=\"_blank\">Staples spikes off buyout report</a> (April 4)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255431\" data-linked=\"Staples +14% with PE interest in the mix\" data-tweet=\"$SPLS - Staples +14% with PE interest in the mix https://seekingalpha.com/news/3255431-staplesplus-14-pe-interest-in-mix?source=tweet\" data-url=\"https://seekingalpha.com/news/3255431-staplesplus-14-pe-interest-in-mix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255430\" data-ts=\"1491314685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADPT\" target=\"_blank\">ADPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255430-medical-properties-trust-gains-on-plans-for-adeptus-lease-restructuring\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medical Properties Trust gains on plans for Adeptus lease restructuring</a></h4><ul><li>Ahead of what's expected to be a Chapter 11 filing from Adeptus (<a href='https://seekingalpha.com/symbol/ADPT' title='Adeptus Health'>ADPT</a> <font color='red'>-51.3%</font>), its 2nd-largest owner (about 10%) - Deerfield Management - <a href=\"https://seekingalpha.com/pr/16790162-medical-properties-trust-inc-describes-plans-restructuring-adeptus-health-inc-leases\" target=\"_blank\">has bought up all of</a> its senior debt with hopes to take control of the company or its key assets.</li><li>Medical Properties Trust (<a href='https://seekingalpha.com/symbol/MPW' title='Medical Properties Trust, Inc.'>MPW</a> <font color='green'>+1.3%</font>) and Deerfield have come to agreement on leases and rent which involves payment of some money to MPT and the re-leasing of some of the facilities.</li><li>MPT CEO Edward Aldag: \"We are very pleased, but not surprised, at the number of sophisticated and well capitalized investors and operators that have been attracted to our market-dominant portfolio of free-standing emergency facilities.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3255430\" data-linked=\"Medical Properties Trust gains on plans for Adeptus lease restructuring\" data-tweet=\"$ADPT $ADPT-RETIRED $MPW - Medical Properties Trust gains on plans for Adeptus lease restructuring https://seekingalpha.com/news/3255430-medical-properties-trust-gains-on-plans-for-adeptus-lease-restructuring?source=tweet\" data-url=\"https://seekingalpha.com/news/3255430-medical-properties-trust-gains-on-plans-for-adeptus-lease-restructuring\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255427\" data-ts=\"1491314458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255427-multi-year-low-for-l-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Multi-year low for L Brands</a></h4><ul> <li>Citi lowers L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>) to a Neutral rating after having the store chain set at Buy previously.</li> <li>Analyst Paul Lejuez says the company has too many stores and warns that mall traffic trends could get worse.</li> <li>The firm takes its price target all the way down to $49 from $70.</li> <li>Shares of L Brands are <font color='red'>down 3.10%</font> to hit their lowest level in about four years.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255427\" data-linked=\"Multi-year low for L Brands\" data-tweet=\"$LB - Multi-year low for L Brands https://seekingalpha.com/news/3255427-multi-year-low-for-l-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3255427-multi-year-low-for-l-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255417\" data-ts=\"1491313675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVOK\" target=\"_blank\">EVOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255417-evoke-pharma-advancing-gimoti-nda-filing-possible-year-end-shares-ahead-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evoke Pharma advancing Gimoti, NDA filing possible by year-end; shares ahead 10%</a></h4><ul><li>Evoke Pharma (<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='green'>+10%</font>) jumps out the blocks on the company's <a href=\"https://seekingalpha.com/filing/3488410\" target=\"_blank\">progress</a> with its New Drug Application &#40;NDA&#41; for Gimoti, its nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women.</li><li>The company met recently with the FDA to finalize the design of a pivotal comparative exposure pharmacokinetic &#40;PK&#41; study and reach agreement on the CMC (Chemistry, Manufacturing &amp; Controls) section of the filing. The aim of the PK trial is to show bioequivalence of Gimoti to Reglan tablets. Data are expected in H2. The NDA filing should be made in late Q4 or early Q1 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255417\" data-linked=\"Evoke Pharma advancing Gimoti, NDA filing possible by year-end; shares ahead 10%\" data-tweet=\"$EVOK - Evoke Pharma advancing Gimoti, NDA filing possible by year-end; shares ahead 10% https://seekingalpha.com/news/3255417-evoke-pharma-advancing-gimoti-nda-filing-possible-year-end-shares-ahead-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3255417-evoke-pharma-advancing-gimoti-nda-filing-possible-year-end-shares-ahead-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255416\" data-ts=\"1491313556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255416-citi-rings-register-on-bofa-shares-slip-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi rings the register on BofA; shares slip early</a></h4><ul><li>Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-0.7%</font>) may have been the cheapest bank stock on election day, but not any longer, says Citi's Keith Horowitz, <a href=\"https://www.streetinsider.com/Analyst+Comments/Citi+Downgrades+Bank+of+America+%28BAC%29+to+Neutral/12740173.html\" target=\"_blank\">downgrading to</a> Neutral from Buy.</li><li>Outperformance since Nov. 9 means the valuation gap has been substantially closed, and BofA is now priced for a lot of good news like reflation, higher rates, and hitting its expense targets.</li><li>Horowitz's $25 price target compares to the current $23.44.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255416\" data-linked=\"Citi rings the register on BofA; shares slip early\" data-tweet=\"$BAC - Citi rings the register on BofA; shares slip early https://seekingalpha.com/news/3255416-citi-rings-register-on-bofa-shares-slip-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3255416-citi-rings-register-on-bofa-shares-slip-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255415\" data-ts=\"1491313151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLS\" target=\"_blank\">SPLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255415-staples-spikes-off-buyout-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Staples spikes off buyout report</a></h4><ul><li>Staples (<a href='https://seekingalpha.com/symbol/SPLS' title='Staples, Inc.'>SPLS</a> <font color='green'>+12.2%</font>) spikes off a Dow Jones report that the company is in talks with buyout firms.</li><li>The story is still developing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255415\" data-linked=\"Staples spikes off buyout report\" data-tweet=\"$SPLS - Staples spikes off buyout report https://seekingalpha.com/news/3255415-staples-spikes-off-buyout-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3255415-staples-spikes-off-buyout-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255405\" data-ts=\"1491312304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255405-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-36%</font>&nbsp;on bankruptcy proceedings.</li><li><a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-15%</font>&nbsp;on results from Phase 2 study evaluating Indoximod in combination with Keytruda.</li><li><a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a> <font color='red'>-12%</font>&nbsp;on extending its pending sales process.</li><li><a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a> <font color='red'>-12%</font>&nbsp;on FQ2 earnings.</li><li><a href='https://seekingalpha.com/symbol/SDLP' title='Seadrill Partners, LLC'>SDLP</a> <font color='red'>-12%</font>.</li><li><a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a> <font color='red'>-5%</font>.</li><li>EBIO <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3255405\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$SDRL $NLNK $KATE - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3255405-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3255405-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255406\" data-ts=\"1491312107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255406-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+40%</font>&nbsp;on&nbsp;on <a href=\"https://seekingalpha.com/news/3255280-new-concept-energy-reports-fy-results\" target=\"_blank\">FY earnings</a>.</li>     <li><a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='green'>+34% </font>on reporting Phase 3 study of&nbsp;omadacycline&nbsp;in community-acquired bacterial pneumonia.</li>     <li><a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+22%.&nbsp;</font></li>     <li><a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a> <font color='green'>+22%</font>&nbsp;on&nbsp; on <a href=\"https://seekingalpha.com/news/3255328-conns-beats-0_17-beats-revenue\" target=\"_blank\">Q4 earnings</a> beat.</li>     <li><a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+24%</font>&nbsp;on&nbsp;on being awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications.</li>     <li><a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+17%</font>&nbsp;on&nbsp;Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor.</li>     <li><a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a> <font color='green'>+16%</font>&nbsp;on positive Type A Meeting with FDA Confirms Acceptability of Pharma&rsquo;s Proposed Comparative Exposure PK Trial for Gimoti NDA.</li>     <li><a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='green'>+13%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color='green'>+7%</font>&nbsp;on&nbsp;reporting new insights into the mechanism of action of its hepatitis B virus-optimized cyclophilin inhibitor CRV431.</li>     <li><a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255406\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$GBR $PRTK $CYCC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3255406-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3255406-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255407\" data-ts=\"1491312045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255407-investors-unimpressed-newlinks-mid-stage-indoximod-data-shares-slip-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors unimpressed with NewLink&#39;s mid-stage indoximod data; shares slip 14% premarket</a></h4><ul><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) is down&nbsp;<font color='red'>14%</font>&nbsp;premarket on increased volume in apparent response to <a href=\"https://seekingalpha.com/pr/16789825-interim-phase-2-data-demonstrate-robust-response-rate-indoximod-combination-keytruda\" target=\"_blank\">interim results</a> from a Phase 2 clinical trial assessing IDO pathway inhibitor indoximod, in combination with Merck's Keytruda (pembrolizumab), in patients with advanced melanoma. The data will be presented today at the American Association for Cancer Research Annual Meeting in Washington, DC.</li><li>In 60 evaluable patients, the objective response rate &#40;ORR&#41; was 52% (n=31/60) and the disease control rate &#40;DCR&#41; was 73% (n=44/60) (DCR includes complete responders, partial responders and those with stable disease). The DCR was not much better than Keytruda alone (<a href=\"https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf\" target=\"_blank\">package insert</a>).</li><li>The company is currently evaluating indoximod in multiple combination studies in a range of cancers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255407\" data-linked=\"Investors unimpressed with NewLink&#39;s mid-stage indoximod data; shares slip 14% premarket\" data-tweet=\"$NLNK - Investors unimpressed with NewLink&#39;s mid-stage indoximod data; shares slip 14% premarket https://seekingalpha.com/news/3255407-investors-unimpressed-newlinks-mid-stage-indoximod-data-shares-slip-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3255407-investors-unimpressed-newlinks-mid-stage-indoximod-data-shares-slip-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255402\" data-ts=\"1491311479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255402-amtrust-up-12-after-getting-restatement-out-of-way\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmTrust up 12% after getting restatement out of the way</a></h4><ul><li>The company is again current with all market listing requirements <a href=\"https://seekingalpha.com/pr/16789462-amtrust-financial-services-inc-completes-annual-financial-restatements-filing-form-10-k\" target=\"_blank\">after filing its</a> 10-K for 2016 and restating 2014 and 2015.</li><li>The restatements results in a decline in net income in 2014 of 7.2%, and in 2015 of 11.2%.</li><li>Gross written premium, net earned premium, loss and loss adjustment expense and loss ratio for 2016, and reserves as of Dec. 31, 2016 remain unchanged from what the company reported in late February.</li><li><a href=\"https://seekingalpha.com/filing/3488336\" target=\"_blank\">This 10-K </a>and all SEC filings hosted on Seeking Alpha</li><li><a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a>&nbsp;<font color='green'>+12.2%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3255402\" data-linked=\"AmTrust up 12% after getting restatement out of the way\" data-tweet=\"$AFSI - AmTrust up 12% after getting restatement out of the way https://seekingalpha.com/news/3255402-amtrust-up-12-after-getting-restatement-out-of-way?source=tweet\" data-url=\"https://seekingalpha.com/news/3255402-amtrust-up-12-after-getting-restatement-out-of-way\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255397\" data-ts=\"1491310399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255397-galenas-neuvax-well-tolerated-in-mid-stage-breast-cancer-study-shares-ahead-13-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena&#39;s NeuVax well-tolerated in mid-stage breast cancer study; shares ahead 13% premarket</a></h4><ul><li>Nano cap Galena Biopharma (GALE) perks up&nbsp;<font color='green'>13%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16789549-galena-biopharma-presents-positive-interim-safety-data-neuvax-nelipepimut-s-clinical-trial\" target=\"_blank\">announcement </a>of positive safety data from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> assessing NeuVax (nelipepimut-S), combined with trastuzumab (Roche's <a href=\"http://www.herceptin.com/\" target=\"_blank\">Herceptin</a>), to prevent recurrence in HER2-positive (HER2 3+) breast cancer patients. The results were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.</li><li>The interim analysis showed that NeuVax was well-tolerated with no increased cardiotoxicity. There were no significant differences in toxicities between the vaccine group (n=22) and control group (n=28), although the incidences of Grade 2 (moderate) and Grade 3 (severe, not life-threatening) were slightly higher in the NeuVax cohort (3.2% vs. 1.5% and 0.8% vs. 0%, respectively). There was no significant difference in cardiac ejection fraction pre- to post-treatment in either group.</li><li>Enrollment should be completed by year-end. According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint of disease-free survival is October 2018. The estimated study completion date is October 2019.</li><li><a href=\"http://galenabiopharma.com/pipeline/neuvax/\" target=\"_blank\">NeuVax&nbsp;</a>is an HER2-directed immunotherapy being investigated for the prevention of breast cancer recurrence after standard-of-care treatment in the adjuvant setting.&nbsp;<a href=\"http://www.cancer.gov/cancertopics/types/breast/adjuvant-fact-sheet\" target=\"_blank\">Adjuvant therapy</a>&nbsp;is any treatment given after primary (first-line) therapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255397\" data-linked=\"Galena&#39;s NeuVax well-tolerated in mid-stage breast cancer study; shares ahead 13% premarket\" data-tweet=\"$SLS - Galena&#39;s NeuVax well-tolerated in mid-stage breast cancer study; shares ahead 13% premarket https://seekingalpha.com/news/3255397-galenas-neuvax-well-tolerated-in-mid-stage-breast-cancer-study-shares-ahead-13-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3255397-galenas-neuvax-well-tolerated-in-mid-stage-breast-cancer-study-shares-ahead-13-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255386\" data-ts=\"1491309263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMFC\" target=\"_blank\">NMFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255386-new-mountain-financeminus-2_7-after-equity-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Mountain Finance -2.7% after equity raise</a></h4><ul><li>New Mountain (NYSE:<a href='https://seekingalpha.com/symbol/NMFC' title='New Mountain Finance'>NMFC</a>) sold <a href=\"https://seekingalpha.com/pr/16789783-new-mountain-finance-corporation-announces-pricing-5000-000-shares-common-stock\" target=\"_blank\">5M shares for $14.60 each</a>. The underwriters have a greenshoe option for another 750K shares at that price.</li><li>The stock's&nbsp;<font color='red'>down 2.7%</font>&nbsp;premarket to $14.55.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255249-capital-raise-new-mountain-finance-shares-minus-3-percent-hours\" target=\"_blank\">Capital raise at New Mountain Finance; shares -3% after hours</a> (April 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3255386\" data-linked=\"New Mountain Finance -2.7% after equity raise\" data-tweet=\"$NMFC - New Mountain Finance -2.7% after equity raise https://seekingalpha.com/news/3255386-new-mountain-financeminus-2_7-after-equity-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3255386-new-mountain-financeminus-2_7-after-equity-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255385\" data-ts=\"1491309233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XYL\" target=\"_blank\">XYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255385-xylem-hosts-investor-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xylem hosts investor meeting</a></h4><ul><li>Reaffirms FY17 outlook: Adjusted EPS of $2.20-$2.35, on revenues of $4.5B-$4.6B, up 20%-22% from 2016.</li><li>Continues to project full-year 2017 adjusted operating margin to be in the range of 13.2%-13.7%.</li><li>Will combine Analytics, Sensus, Visenti businesses, and report their financial and operational results as one segment.</li><li><a href='https://seekingalpha.com/symbol/XYL' title='Xylem, Inc.'>XYL</a> <font color='green'>+2.1%</font> premarket</li><li>Webcast at 9 a.m. ET is available <a href=\"https://6connex.webcasts.com/starthere.jsp?ei=1141960\" target=\"_blank\">here</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3255385\" data-linked=\"Xylem hosts investor meeting\" data-tweet=\"$XYL - Xylem hosts investor meeting https://seekingalpha.com/news/3255385-xylem-hosts-investor-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3255385-xylem-hosts-investor-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255381\" data-ts=\"1491308818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255381-parateks-omadacycline-successful-in-late-stage-cabp-study-shares-jump-36-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paratek&#39;s omadacycline successful in late-stage CABP study; shares jump 36% premarket</a></h4><ul><li>Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) is up&nbsp;<font color='green'>36%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16789025-paratek-announces-positive-phase-3-study-omadacycline-community-acquired-bacterial-pneumonia\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial assessing its investigational broad spectrum antibiotic omadacycline for the treatment of community-acquired bacterial pneumonia &#40;CABP&#41;.</li><li>The study met all primary and secondary endpoints. Data from this trial and another in skin infections will support marketing applications in the U.S. and Europe.</li><li>The company says it plans to file an NDA with the FDA as early as Q1 2018, followed by an MAA in Europe later that year.</li><li>Omadacycline, a&nbsp;<a href=\"https://en.wikipedia.org/wiki/Tetracycline\" target=\"_blank\">tetracycline</a>&nbsp;antibiotic known as an&nbsp;<a href=\"http://www.paratekpharm.com/pdf/Mechanism%20of%20Action%20of%20the%20Novel%20Aminomethylcycline%20Antibiotic%20Omadacycline.pdf\" target=\"_blank\">aminomethylcycline</a>, has broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255381\" data-linked=\"Paratek&#39;s omadacycline successful in late-stage CABP study; shares jump 36% premarket\" data-tweet=\"$PRTK - Paratek&#39;s omadacycline successful in late-stage CABP study; shares jump 36% premarket https://seekingalpha.com/news/3255381-parateks-omadacycline-successful-in-late-stage-cabp-study-shares-jump-36-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3255381-parateks-omadacycline-successful-in-late-stage-cabp-study-shares-jump-36-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255380\" data-ts=\"1491308775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255380-indonesia-allows-exports-from-freeport-mine-in-temporary-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Indonesia allows exports from Freeport mine in temporary deal</a></h4><ul>     <li>Freeport McMoRan (NYSE:<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a>) <font color='green'>+3.7%</font> premarket after the Indonesian government <a href=\"https://www.bloomberg.com/news/articles/2017-04-04/indonesia-gives-freeport-temporary-license-to-resume-exports\" target=\"_blank\">issues a temporary mining license</a> that will allow the company to resume concentrate exports from the Grasberg copper mine for the first time since January.</li>     <li>The permit is valid for eight months from the time that FCX was first offered a special mining license in February,while the government will continue talks with the company on a long-term financial stability pact, an official says.</li>     <li>The interim deal could allow FCX to restore operations at Grasberg to full capacity; the miner currently operates the mine at ~40% to feed a smelter in Gresik on Java island.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3255380\" data-linked=\"Indonesia allows exports from Freeport mine in temporary deal\" data-tweet=\"$FCX $FCX $JJCTF - Indonesia allows exports from Freeport mine in temporary deal https://seekingalpha.com/news/3255380-indonesia-allows-exports-from-freeport-mine-in-temporary-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3255380-indonesia-allows-exports-from-freeport-mine-in-temporary-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255375\" data-ts=\"1491308159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255375-fda-oks-tevas-austedo-for-hd-chorea-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Teva&#39;s Austedo for HD chorea; shares ahead 2% premarket</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16789194-teva-announces-fda-approval-austedo-deutetrabenazine-tablets-treatment-chorea-associated\" target=\"_blank\">announcement </a>that the FDA has approved AUSTEDO (deutetrabenazine) tablets for the treatment of <a href=\"https://en.wikipedia.org/wiki/Chorea\" target=\"_blank\">chorea</a> (abnormal involuntary movements) associated with Huntington's disease &#40;HD&#41;, an Orphan Drug indication.</li><li>HD is a neurodegenerative disease that affects more than 35K Americans each year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255375\" data-linked=\"FDA OKs Teva&#39;s Austedo for HD chorea; shares ahead 2% premarket\" data-tweet=\"$TEVA - FDA OKs Teva&#39;s Austedo for HD chorea; shares ahead 2% premarket https://seekingalpha.com/news/3255375-fda-oks-tevas-austedo-for-hd-chorea-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3255375-fda-oks-tevas-austedo-for-hd-chorea-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255374\" data-ts=\"1491308025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAT\" target=\"_blank\">CAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255374-cat-added-to-goldmans-conviction-buy-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CAT added to Goldman&#39;s Conviction Buy list</a></h4><ul><li>Caterpillar (NYSE:<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a>) <font color='green'>+1.3%</font> premarket after Goldman upgraded the stock to its Conviction Buy list with a PT&nbsp;of $120, citing an \"attractive combination\" of higher mid-cycle EPS.</li><li>The firm believes mining machinery demand is at an inflection and construction machinery market demand is in the early stages of a recovery, with significant opportunity for inventory restock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255374\" data-linked=\"CAT added to Goldman&#39;s Conviction Buy list\" data-tweet=\"$CAT - CAT added to Goldman&#39;s Conviction Buy list https://seekingalpha.com/news/3255374-cat-added-to-goldmans-conviction-buy-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3255374-cat-added-to-goldmans-conviction-buy-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255372\" data-ts=\"1491307573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255372-urban-outfitters-lower-after-sales-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters lower after sales update</a></h4><ul> <li>Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) says it sees Q1 comparable retail segment sales falling at a mid-single-digit pace. The disclosure was part of the company's 10-K filing.</li> <li>Citi lowers its rating on the retailer to Neutral after having it slotted at Buy.</li> <li><a href=\"https://seekingalpha.com/filing/3487038\" target=\"_blank\">SEC Form 10-K</a></li> <li>URBN <font color='red'>-5.04%</font> premarket to $22.03.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255372\" data-linked=\"Urban Outfitters lower after sales update\" data-tweet=\"$URBN - Urban Outfitters lower after sales update https://seekingalpha.com/news/3255372-urban-outfitters-lower-after-sales-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3255372-urban-outfitters-lower-after-sales-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255370\" data-ts=\"1491307544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255370-nvidiaminus-3-pacific-crest-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia -3% as Pacific Crest cuts to Underweight</a></h4><ul><li>Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <font color='red'>-2.9%</font> premarket after Pacific Crest <a href=\"http://www.marketwatch.com/story/nvidias-stock-drops-after-analyst-downgrade-to-bearish-rating-2017-04-04\" target=\"_blank\">downgrades</a> shares to Underweight from Sector Weight, citing concerns that it may have captured  so much of the available market that growth could become a problem.</li><li>Crest analyst Michael McConnell says he is concerned about \"signs of desktop [graphics  processing unit] market saturation, lower margins from incremental  Nintendo Switch revenue and a possible pause in the company's datacenter  business this summer.\"</li><li>McConnell says <a href=\"https://twitter.com/thenotablecalls/status/849223731209793537\" target=\"_blank\">desktop GPU demand slowed in Q1</a>, with sales to China down 30%-40% Q/Q and ~20% lower to the U.S., with channel inventory to blame.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255370\" data-linked=\"Nvidia -3% as Pacific Crest cuts to Underweight\" data-tweet=\"$NVDA - Nvidia -3% as Pacific Crest cuts to Underweight https://seekingalpha.com/news/3255370-nvidiaminus-3-pacific-crest-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3255370-nvidiaminus-3-pacific-crest-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255359\" data-ts=\"1491307533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255359-new-studies-support-functional-cure-of-contravirs-hbv-candidate-crv431-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New studies support functional cure of ContraVir&#39;s HBV candidate CRV431; shares ahead 8% premarket</a></h4><ul><li>ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) is up&nbsp;<font color='green'>8%&nbsp;</font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16789431-contravir-s-cyclophilin-inhibitor-crv431-targets-hepatitis-b-surface-antigen-hbsag\" target=\"_blank\">announcement </a>of new study data performed at the Scripps Research Institute that clarify the mechanism of action of CRV431, one of the company's candidates for the functional cure of hepatitis B virus &#40;HBV&#41; infection.</li><li>Results show that CRV431 blocks the interaction between hepatitis B surface antigen (HBsAg) and a key cellular protein called cyclophilin A. High levels of HBsAg is a predictor of disease progression leading to liver fibrosis, cirrhosis and cancer.</li><li>ContraVir's \"functional cure\" strategy for chronic HBV infection is based on combining drugs with complementary mechanisms of action. TXL (tenofovir exalidex prodrug), for example, works by lowering infectious virus in the blood. CRV431 complements TXL's activity by targeting HBsAg, possibly increasing the likelihood that the patient's immune system can kill the virus.</li><li>Phase 2-stage TXL is a prodrug of Gilead Sciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) <a href=\"http://www.viread.com/\" target=\"_blank\">VIREAD </a>(tenofovir disoproxil fumarate). CRV431 is a next-generation cyclophilin inhibitor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255359\" data-linked=\"New studies support functional cure of ContraVir&#39;s HBV candidate CRV431; shares ahead 8% premarket\" data-tweet=\"$CTRV $HEPA $GILD - New studies support functional cure of ContraVir&#39;s HBV candidate CRV431; shares ahead 8% premarket https://seekingalpha.com/news/3255359-new-studies-support-functional-cure-of-contravirs-hbv-candidate-crv431-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3255359-new-studies-support-functional-cure-of-contravirs-hbv-candidate-crv431-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255363\" data-ts=\"1491307221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISCA\" target=\"_blank\">ISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255363-on-international-speedways-fq1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on International Speedway&#39;s FQ1</a></h4><ul>     <li>International Speedway (NASDAQ:<a href='https://seekingalpha.com/symbol/ISCA' title='International Speedway Corporation'>ISCA</a>)&nbsp;reports admission revenue fell 1.63% to $31.34M in <a href=\"https://seekingalpha.com/pr/16789593-international-speedway-corporation-reports-financial-results-first-quarter-fiscal-2017\" target=\"_blank\">FQ1</a>.</li>     <li>Motorsports&nbsp;and other event related&nbsp;revenue expanded 4.85% to $103.51M.</li>     <li>Food, beverage, and merchandise revenue rose 9.93% to $9.14M.</li>     <li>Operating margin rate +100 bps to 22.9%.</li>     <li><b>FY2017 Guidance</b>: Revenue: $660M to $670M; Non-GAAP EBITDA: $208M to $218M; EBITDA margin: 31.5% to 32.5%; Operating margin: 15.5% to 17%; Tax rate: 38% to 38.5%; Diluted EPS: $1.50 to $1.65; Capex: ~$150M to $175M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255363\" data-linked=\"More on International Speedway&#39;s FQ1\" data-tweet=\"$ISCA - More on International Speedway&#39;s FQ1 https://seekingalpha.com/news/3255363-on-international-speedways-fq1?source=tweet\" data-url=\"https://seekingalpha.com/news/3255363-on-international-speedways-fq1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255361\" data-ts=\"1491306742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHIP\" target=\"_blank\">SHIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255361-seanergy-maritime-acquires-modern-capesize-vessel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seanergy Maritime acquires modern capesize vessel</a></h4><ul> <li>Seanergy Maritime Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/SHIP' title='Seanergy Maritime Holdings Corp'>SHIP</a>) announces that it has entered into an agreement with an unaffiliated third party for the purchase of a secondhand Capesize vessel for $32.65M.</li> <li>The vessel is expected to be delivered by the end of May.</li><li>The company expects to fund the purchase through a secured loan facility from financial institutions and financing arrangements with the company's sponsor.</li> <li>\"This purchase allows us to expand further our sizable position in the Capesize segment. We strongly believe that the Capesize segment represents the best fundamentals in the dry bulk industry and we will continue to actively pursue accretive acquisition opportunities of quality Capesize vessels with an aim of increasing value for our shareholders,\" says CEO Stamatis Tsantanis.</li>  <li>SHIP  <font color='green'>+30.93%</font> premarket to  $1.09.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16789595-seanergy-maritime-holdings-corp-announces-agreement-acquire-modern-capesize-vessel\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3255361\" data-linked=\"Seanergy Maritime acquires modern capesize vessel\" data-tweet=\"$SHIP - Seanergy Maritime acquires modern capesize vessel https://seekingalpha.com/news/3255361-seanergy-maritime-acquires-modern-capesize-vessel?source=tweet\" data-url=\"https://seekingalpha.com/news/3255361-seanergy-maritime-acquires-modern-capesize-vessel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255347\" data-ts=\"1491304961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRUS\" target=\"_blank\">CRUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255347-cirrus-logic-skyworks-higher-premarket-after-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cirrus Logic, Skyworks higher premarket after upgrades</a></h4><ul><li>Recent channel checks show lean carrier iPhone 7 inventories and little-to-no pricing pressures, says Pac Crest's John Vinh, upgrading Cirrus Logic (NASDAQ:<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a>) and Skyworks (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>) to Overweight. The low inventories could drive greater-than-normal seasonality in H2.</li><li>His $75 price target on Cirrus suggests&nbsp;<font color='green'>25% upside</font>, and $120 on Skyworks,&nbsp;<font color='green'>23% upside</font>.</li><li>CRUS<font color='green'> +1.6%</font>, SWKS&nbsp;<font color='green'>+0.7%</font>&nbsp;premarket</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3255347\" data-linked=\"Cirrus Logic, Skyworks higher premarket after upgrades\" data-tweet=\"$CRUS $CRUS $SWKS - Cirrus Logic, Skyworks higher premarket after upgrades https://seekingalpha.com/news/3255347-cirrus-logic-skyworks-higher-premarket-after-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3255347-cirrus-logic-skyworks-higher-premarket-after-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255342\" data-ts=\"1491303875\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255342-redhills-yeliva-orphan-drug-for-bile-duct-cancer-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill&#39;s Yeliva an Orphan Drug for bile duct cancer; shares ahead 7% premarket</a></h4><ul><li>RedHill Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16789456-redhill-biopharma-receives-fda-orphan-drug-designation-yeliva-treatment-cholangiocarcinoma\" target=\"_blank\">announcement </a>that the FDA has designated YELIVA (ABC294640) an Orphan Drug for the treatment of cholangiocarcinoma (bile duct cancer). A Phase 2a clinical trial is expected to be initiated in Q3.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.</li><li>Orally available YELIVA inhibits an enzyme called sphingosine kinase-2 (SK2). Blocking the activity of SK2 interferes with the synthesis of a lipid called sphingosine 1-phosphate (S1P) which promotes cancer growth and inflammation.</li><li>Bile duct cancer strikes ~8K Americans each year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255342\" data-linked=\"RedHill&#39;s Yeliva an Orphan Drug for bile duct cancer; shares ahead 7% premarket\" data-tweet=\"$RDHL - RedHill&#39;s Yeliva an Orphan Drug for bile duct cancer; shares ahead 7% premarket https://seekingalpha.com/news/3255342-redhills-yeliva-orphan-drug-for-bile-duct-cancer-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3255342-redhills-yeliva-orphan-drug-for-bile-duct-cancer-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255334\" data-ts=\"1491302779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CONN\" target=\"_blank\">CONN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255334-on-conns-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Conn&#39;s Q4</a></h4><ul>     <li>Conn's (NASDAQ:<a href='https://seekingalpha.com/symbol/CONN' title='Conn&#39;s, Inc.'>CONN</a>) reports same-store sales declined 8.9% in <a href=\"https://seekingalpha.com/pr/16789428-conns-inc-reports-fourth-quarter-fiscal-2017-financial-results\" target=\"_blank\">Q4</a>.</li>     <li>Net sales by category:&nbsp;Furniture and mattress: $111.29M (-3.8%);&nbsp;Home appliance: $83.72M (-5.8%);&nbsp;Consumer electronics: $96.42M (-4.2%); Home office: $25.48M (-16%); Other: $5.02M (-3%);&nbsp;Repair service agreement commissions: $30.77M (-4.3%);&nbsp;Service revenues: $3.2M (-14.4%).</li>     <li>Credit revenue slipped 4.1% to $76.6M.</li>     <li>Furniture unit volume fell 18.4% &amp; mattress unit volume -13.5%.</li>     <li>Home appliance unit volume dropped 6.9%.</li>     <li>Consumer electronic&nbsp;unit volume squeezed 9.7%.</li>     <li>Home office unit volume curbed 13.6%.</li>     <li>Retail gross margin expanded 280 bps to 38.9%.</li>     <li>Operating margin grew 380 bps to 15.7%.</li>     <li>Retail store count +10 Y/Y to 113.</li>     <li><b>FY2017 Guidance</b>: Same-store sales:&nbsp;down mid-teens;&nbsp;Retail gross margin rate: 37.5% to 38%; SG&amp;A expense rate: 30.5% to 32%;&nbsp;Provision for bad debts: $56M to $60M;&nbsp;Finance charges and other revenues: $74M to $78M;&nbsp;Interest expense: $22.5M to $24M</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255334\" data-linked=\"More on Conn&#39;s Q4\" data-tweet=\"$CONN - More on Conn&#39;s Q4 https://seekingalpha.com/news/3255334-on-conns-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3255334-on-conns-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255318\" data-ts=\"1491295241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGTY\" target=\"_blank\">IMGTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255318-imagination-technologies-takeover-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imagination Technologies - a takeover target?</a></h4><ul><li>Shares in Imagination Tech (<a href='https://seekingalpha.com/symbol/IMGTY' title='Imagination Technology Group PLC ADR'>OTC:IMGTY</a>) are <font color='green'>up 5.6%</font> in London on a report it could become a takeover target.</li><li>Credit Suisse upgraded its rating on the firm, saying it saw potential M&amp;A interest from Chinese suitors.</li><li>The call comes after Apple terminated its contract with the company, sending the stock into free-fall in yesterday's trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255318\" data-linked=\"Imagination Technologies - a takeover target?\" data-tweet=\"$IMGTY $IGNMF - Imagination Technologies - a takeover target? https://seekingalpha.com/news/3255318-imagination-technologies-takeover-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3255318-imagination-technologies-takeover-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":60,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}